JP2022172244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022172244A5 JP2022172244A5 JP2022137454A JP2022137454A JP2022172244A5 JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5 JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022137454 A JP2022137454 A JP 2022137454A JP 2022172244 A5 JP2022172244 A5 JP 2022172244A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- hcv
- genotype
- hcv genotype
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024130501A JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361823712P | 2013-05-15 | 2013-05-15 | |
| US61/823,712 | 2013-05-15 | ||
| US201361887229P | 2013-10-04 | 2013-10-04 | |
| US61/887,229 | 2013-10-04 | ||
| JP2021001926A JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021001926A Division JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024130501A Division JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022172244A JP2022172244A (ja) | 2022-11-15 |
| JP2022172244A5 true JP2022172244A5 (enExample) | 2023-07-28 |
Family
ID=54054625
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2022137454A Pending JP2022172244A (ja) | 2013-05-15 | 2022-08-31 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513459A Withdrawn JP2016520077A (ja) | 2013-05-15 | 2014-05-15 | Ｅ１ｅ２ｈｃｖワクチン及び使用方法 |
| JP2019087976A Withdrawn JP2019142962A (ja) | 2013-05-15 | 2019-05-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
| JP2021001926A Pending JP2021059596A (ja) | 2013-05-15 | 2021-01-08 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024130501A Pending JP2024156917A (ja) | 2013-05-15 | 2024-08-07 | Ｅ１ｅ２ ｈｃｖワクチン及び使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20210145963A9 (enExample) |
| EP (2) | EP2996718B1 (enExample) |
| JP (5) | JP2016520077A (enExample) |
| CN (2) | CN112999344A (enExample) |
| AU (3) | AU2014385320B2 (enExample) |
| CA (1) | CA2909586C (enExample) |
| CL (1) | CL2015003333A1 (enExample) |
| WO (1) | WO2015132619A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491735A3 (en) * | 2015-10-08 | 2025-04-16 | The Governors of the University of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| CN109963587A (zh) * | 2016-09-21 | 2019-07-02 | 艾伯塔大学理事会 | 丙型肝炎病毒免疫原性组合物及其使用方法 |
| AU2017341735B2 (en) | 2016-10-11 | 2022-01-13 | Helmholtz Center for Infection Research | Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof |
| EP3765075A4 (en) | 2018-03-16 | 2021-12-08 | The Governors of the University of Alberta | HEPATITIS C VIRUS PEPTIDE COMPOSITIONS AND METHOD OF USING THEREOF |
| WO2025222304A1 (en) * | 2024-04-26 | 2025-10-30 | The Governors Of The University Of Alberta | Hcv genotype3 e2 envelope protein for neutralizing infectivity of hcv strains |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| EP0689454B2 (en) | 1993-03-23 | 2005-02-23 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DE69535905D1 (de) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatorische Oligonukleotide |
| WO1996004301A2 (en) | 1994-07-29 | 1996-02-15 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| EP0930893B1 (en) | 1996-10-11 | 2005-04-13 | The Regents of The University of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| WO1998050556A2 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
| WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| JP4101888B2 (ja) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法 |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
| KR100642044B1 (ko) | 1999-03-19 | 2006-11-10 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| CN1227030C (zh) | 1999-04-19 | 2005-11-16 | 史密丝克莱恩比彻姆生物有限公司 | 包含皂甙和免疫刺激寡核苷酸的佐剂组合物 |
| BR0014285A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico |
| PL355163A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| AU2002322358B2 (en) * | 2001-06-29 | 2009-06-18 | Novartis Vaccines And Diagnostics, Inc. | HCV E1E2 vaccine compositions |
| US7348011B2 (en) * | 2005-06-10 | 2008-03-25 | Sudershan Biotech Ltd. | Hepatitis C virus vaccine |
| WO2007041432A2 (en) * | 2005-09-30 | 2007-04-12 | Novartis Vaccines And Diagnostics, Inc. | Cross-neutralization of hcv with recombinant proteins |
| WO2009061739A1 (en) * | 2007-11-06 | 2009-05-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralization of hcv |
| WO2014060851A2 (en) * | 2012-10-05 | 2014-04-24 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
-
2014
- 2014-05-15 JP JP2016513459A patent/JP2016520077A/ja not_active Withdrawn
- 2014-05-15 CA CA2909586A patent/CA2909586C/en active Active
- 2014-05-15 AU AU2014385320A patent/AU2014385320B2/en active Active
- 2014-05-15 EP EP14884476.4A patent/EP2996718B1/en active Active
- 2014-05-15 WO PCT/IB2014/001972 patent/WO2015132619A1/en not_active Ceased
- 2014-05-15 CN CN202110252076.3A patent/CN112999344A/zh active Pending
- 2014-05-15 CN CN201480027001.3A patent/CN105263517B/zh active Active
- 2014-05-15 US US14/783,699 patent/US20210145963A9/en not_active Abandoned
- 2014-05-15 EP EP19215826.9A patent/EP3689375A1/en not_active Withdrawn
-
2015
- 2015-11-13 CL CL2015003333A patent/CL2015003333A1/es unknown
-
2019
- 2019-05-08 JP JP2019087976A patent/JP2019142962A/ja not_active Withdrawn
-
2020
- 2020-01-10 AU AU2020200216A patent/AU2020200216A1/en not_active Abandoned
-
2021
- 2021-01-08 JP JP2021001926A patent/JP2021059596A/ja active Pending
-
2022
- 2022-02-04 AU AU2022200747A patent/AU2022200747A1/en not_active Abandoned
- 2022-03-23 US US17/702,231 patent/US20230098265A1/en not_active Abandoned
- 2022-08-31 JP JP2022137454A patent/JP2022172244A/ja active Pending
-
2023
- 2023-11-27 US US18/520,057 patent/US20240316186A1/en active Pending
-
2024
- 2024-08-07 JP JP2024130501A patent/JP2024156917A/ja active Pending